COMMUNIQUÉS West-GlobeNewswire

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
30/03/2026
Alignment reached on key elements of ATH434 Phase 3 development program MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the [...]
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
30/03/2026
Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company [...]
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
30/03/2026
Appili Presentation Highlights Recent Collaborations and Funding Milestones Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities HALIFAX, Nova Scotia, March 30, [...]
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
30/03/2026
Court preserves jury’s finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 MENLO PARK, Calif., March 30, 2026 (GLOBE [...]
Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Production Hybrids, Achieving Key Milestone in its Aggressive Scale-Up Plan
30/03/2026
ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced the successful [...]
Connect Biopharma Announces $20.2 Million Private Placement Financing
30/03/2026
Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma [...]
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
30/03/2026
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near ‑ maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to [...]
Micron Biomedical Named to Fast Company’s 2026 List of World’s Most Innovative Companies for Addressing the Most Significant Bottlenecks in How Medicine is Made, Distributed and Administered
30/03/2026
Recognition as second most innovative smaller company across all industries highlights transformative impact on public health, impactful industry collaborations, and a novel manufacturing approach that simplifies access [...]
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
30/03/2026
Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability [...]
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network
30/03/2026
Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network. Emobot's platform [...]
Vireo Growth Inc. Announces Update on Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro
30/03/2026
Planned share-based transaction is expected to be completed during the second quarter of 2026 Vireo plans to appoint ScottsMiracle-Gro EVP Chris Hagedorn to its Board of Directors MINNEAPOLIS, March 30, 2026 (GLOBE [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
30/03/2026
COPENHAGEN, Denmark, March 30, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis
30/03/2026
Significant improvements in pain, function and patient global outcomes demonstrated LEVI-04 well tolerated and exhibits a favourable safety profile SANDWICH, United Kingdom, March 30, 2026 (GLOBE NEWSWIRE) -- Levicept [...]
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
30/03/2026
Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late- [...]
NANOBIOTIX annonce la présentation des premières données de l’étude de phase 2 randomisée évaluant JNJ-1900 (NBTXR3) dans le cancer du poumon inopérable de stade III
30/03/2026
Données présentées par Johnson & Johnson lors de la conférence annuelle européenne 2026 sur le cancer du poumon (ELCC) PARIS et CAMBRIDGE, Mass., 30 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ [...]
Draupnir Bio announces transformational publication detailing extracellular targeted protein degradation technology in Cell Chemical Biology
30/03/2026
Draupnir’s novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against difficult-to-drug targets Study further details platform [...]
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
30/03/2026
The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs. The new test delivers faster turnaround times and [...]
Camila Japur joins Tecan as Chief Financial Officer
30/03/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Camila Japur joins Tecan as Chief Financial Officer Männedorf, Switzerland, March 30, 2026 – The Tecan Group (SIX Swiss Exchange: [...]
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
30/03/2026
Ad hoc announcement pursuant to Art. 53 LR Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep measures in children [...]

Pages